Imatinib is a first-generation small-molecule kinase inhibitor that targets the BCR-ABL protein tyrosine kinase and is primarily used to treat chronic myeloid leukemia (CML) by inhibiting its aberrant kinase activity (Peng et al. 2005; Wang et al. 2021). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.